Brokerages Set Syros Pharmaceuticals Inc (NASDAQ:SYRS) PT at $16.46

Syros Pharmaceuticals Inc (NASDAQ:SYRS) has received an average recommendation of “Buy” from the eleven brokerages that are covering the stock, Marketbeat reports. Two investment analysts have rated the stock with a hold recommendation and eight have given a buy recommendation to the company. The average twelve-month target price among analysts that have issued ratings on the stock in the last year is $16.89.

Several research analysts have recently commented on the company. Roth Capital reiterated a “buy” rating and set a $17.00 price target on shares of Syros Pharmaceuticals in a report on Friday, July 12th. Wedbush reiterated an “outperform” rating on shares of Alphabet in a report on Thursday, April 25th. HC Wainwright reiterated a “neutral” rating on shares of Syros Pharmaceuticals in a report on Thursday, May 2nd. Piper Jaffray Companies set a $44.00 price target on First Merchants and gave the stock a “buy” rating in a report on Wednesday, April 10th. Finally, ValuEngine lowered Yirendai from a “sell” rating to a “strong sell” rating in a report on Wednesday, June 26th.

Shares of NASDAQ SYRS traded down $0.36 during trading on Friday, hitting $7.27. 518 shares of the company were exchanged, compared to its average volume of 301,401. Syros Pharmaceuticals has a 12-month low of $5.17 and a 12-month high of $13.18. The company has a debt-to-equity ratio of 0.02, a current ratio of 5.19 and a quick ratio of 5.19. The company’s fifty day moving average is $7.13. The stock has a market cap of $312.29 million, a price-to-earnings ratio of -3.85 and a beta of 1.95.

Syros Pharmaceuticals (NASDAQ:SYRS) last posted its quarterly earnings results on Wednesday, May 1st. The company reported ($0.49) EPS for the quarter, topping the consensus estimate of ($0.57) by $0.08. Syros Pharmaceuticals had a negative return on equity of 74.28% and a negative net margin of 3,012.04%. The business had revenue of $0.45 million for the quarter, compared to analyst estimates of $0.42 million. On average, analysts anticipate that Syros Pharmaceuticals will post -1.82 EPS for the current year.

Several large investors have recently modified their holdings of SYRS. Rhumbline Advisers increased its position in shares of Syros Pharmaceuticals by 51.4% during the 4th quarter. Rhumbline Advisers now owns 32,406 shares of the company’s stock worth $181,000 after purchasing an additional 10,995 shares during the last quarter. BlackRock Inc. increased its position in shares of Syros Pharmaceuticals by 23.1% during the 4th quarter. BlackRock Inc. now owns 1,986,130 shares of the company’s stock worth $11,063,000 after purchasing an additional 372,462 shares during the last quarter. Bank of New York Mellon Corp increased its position in shares of Syros Pharmaceuticals by 8.9% during the 4th quarter. Bank of New York Mellon Corp now owns 84,537 shares of the company’s stock worth $470,000 after purchasing an additional 6,883 shares during the last quarter. Northern Trust Corp increased its position in shares of Syros Pharmaceuticals by 0.7% during the 4th quarter. Northern Trust Corp now owns 306,167 shares of the company’s stock worth $1,705,000 after purchasing an additional 2,179 shares during the last quarter. Finally, Connor Clark & Lunn Investment Management Ltd. increased its position in shares of Syros Pharmaceuticals by 3.3% during the 4th quarter. Connor Clark & Lunn Investment Management Ltd. now owns 122,561 shares of the company’s stock worth $683,000 after purchasing an additional 3,900 shares during the last quarter. 56.16% of the stock is owned by hedge funds and other institutional investors.

About Syros Pharmaceuticals

Syros Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development of treatment for cancer and monogenic diseases, and building a pipeline of gene control medicines. Its lead product candidates include SY-1425, a selective retinoic acid receptor alpha agonist, which is in a Phase II clinical trial for genomically defined subsets of patients with acute myeloid leukemia (AML) and myelodysplastic syndrome; SY-1365, a selective cyclin-dependent kinase 7 (CDK7) inhibitor, which is in a Phase I clinical trial that is used for treating patients with solid tumors and blood cancers, including ovarian and breast cancer; and SY-5609, a CDK7 inhibitor, which is in preclinical studies to treat oncology patients.

Further Reading: Percentage Decliners

Analyst Recommendations for Syros Pharmaceuticals (NASDAQ:SYRS)

Receive News & Ratings for Syros Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syros Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.